<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092092</url>
  </required_header>
  <id_info>
    <org_study_id>0476-254</org_study_id>
    <secondary_id>2004_023</secondary_id>
    <nct_id>NCT00092092</nct_id>
  </id_info>
  <brief_title>Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)</brief_title>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled, 2-Arm, 2X2 Crossover Study Comparing the Effects of Montelukast, Inhaled Budesonide, and Placebo on Lower Leg Growth in Children (Prepubertal, Tanner Stage I) With Mild Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of montelukast, an approved medication,
      on the lower leg growth rate in children with mild asthma. The primary hypothesis is that the
      lower leg length (LLL) growth rate for children treated with montelukast compared to placebo
      will be established.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a crossover study that consists of a 2-week placebo run-in period, then a first
      3-week treatment period, then a 2-week washout period, and then a second 3-week treatment
      period. Participants will be randomized to treatment with either montelukast and placebo or
      budesonide and placebo. The duration of treatment is 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term lower-leg growth rate (LLGR)</measure>
    <time_frame>Baseline and Week 3</time_frame>
    <description>Lower leg length was measured in millimeters (mm) using a knemometer.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Asthma, Bronchial</condition>
  <arm_group>
    <arm_group_label>Montelukast→Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo→Montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide→Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo→Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast chewable tablets</intervention_name>
    <description>Montelukast sodium 5 mg chewable tablets</description>
    <arm_group_label>Montelukast→Placebo</arm_group_label>
    <arm_group_label>Placebo→Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide inhaler</intervention_name>
    <description>Budesonide 200 mcg inhalation powder</description>
    <arm_group_label>Budesonide→Placebo</arm_group_label>
    <arm_group_label>Placebo→Budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to montelukast chewable tablets</intervention_name>
    <description>Placebo chewable tablets</description>
    <arm_group_label>Montelukast→Placebo</arm_group_label>
    <arm_group_label>Placebo→Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to budesonide inhaler</intervention_name>
    <description>Placebo inhalation powder</description>
    <arm_group_label>Budesonide→Placebo</arm_group_label>
    <arm_group_label>Placebo→Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A 6-month history of asthma with periodic episodes requiring treatment.

        Exclusion Criteria:

          -  Medical history of a lung disorder (other than asthma) or a recent upper respiratory
             tract infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol. 2007 Sep;42(9):838-43.</citation>
    <PMID>17659605</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2004</study_first_submitted>
  <study_first_submitted_qc>September 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2004</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

